Evangelos Terpos researcher
Terpos, Evangelos
Terpos, Evangelos 1967-
VIAF ID: 72152682588223312383 (Personal)
Permalink: http://viaf.org/viaf/72152682588223312383
Preferred Forms
- 100 0 _ ‡a Evangelos Terpos ‡c researcher
- 100 1 _ ‡a Terpos, Evangelos
- 100 1 _ ‡a Terpos, Evangelos
-
-
- 100 1 _ ‡a Terpos, Evangelos ‡d 1967-
4xx's: Alternate Name Forms (2)
5xx's: Related Names (1)
- 510 2 _ ‡a University of Athens School of Medicine ‡4 affi ‡4 https://d-nb.info/standards/elementset/gnd#affiliation ‡e Affiliation
Works
Title | Sources |
---|---|
2021 European Myeloma Network review and consensus statement on smoldering multiple myeloma: how to distinguish (and manage) Dr. Jekyll and Mr. Hyde | |
Cardiovascular adverse events in modern myeloma therapy – incidence and risks. A review from the European Myeloma Network (EMN) and Italian Society of Arterial Hypertension (SIIA) | |
From transplant to novel cellular therapies in multiple myeloma : european myeloma network guidelines and future perspectives | |
Growth Differentiation Factor 15 Is a New Biomarker for Survival and Renal Outcomes in Light Chain (AL) Amyloidosis. | |
Helicobacter pylori infection in patients with nonalcoholic fatty liver disease. | |
Hematologic and renal improvement of monoclonal immunoglobulin deposition disease after treatment with bortezomib-based regimens. | |
Hematological findings and complications of COVID-19 | |
High levels of serum angiogenic growth factors in patients with AL amyloidosis: comparisons with normal individuals and multiple myeloma patients | |
Increased angiogenesis and enhanced bone formation in patients with IgM monoclonal gammopathy and urticarial skin rash: new insight into the biology of Schnitzler syndrome | |
Increased serum lactate dehydrongenase should be included among the variables that define very-high-risk multiple myeloma | |
International myeloma working group consensus recommendations on imaging in monoclonal plasma cell disorders | |
International Myeloma Working Group updated criteria for the diagnosis of multiple myeloma | |
Investigating the Vascular Toxicity Outcomes of the Irreversible Proteasome Inhibitor Carfilzomib | |
Lack of survival improvement with novel anti-myeloma agents for patients with multiple myeloma and central nervous system involvement: the Greek Myeloma Study Group experience | |
Long PFS of more than 7 years is achieved in 9% of myeloma patients in the era of conventional chemotherapy and of first-generation novel anti-myeloma agents: a single-center experience over 20-year period | |
Longer procoagulant phospholipid-dependent clotting time, lower endogenous thrombin potential and higher tissue factor pathway inhibitor concentrations are associated with increased VTE occurrence in patients with newly diagnosed multiple myeloma: re | |
Maintenance Treatment and Survival in Patients With Myeloma: A Systematic Review and Network Meta-analysis | |
Management of bone health in solid tumours: From bisphosphonates to a monoclonal antibody | |
Mechanisms of bone destruction in multiple myeloma. | |
Molecular mechanisms of carfilzomib-induced cardiotoxicity in mice and the emerging cardioprotective role of metformin | |
Multiple myeloma and other plasma cell neoplasms, 2018: | |
Multiple myeloma: Role of autologous transplantation | |
Multiple Myeloma Treatment in Real-world Clinical Practice: Results of a Prospective, Multinational, Noninterventional Study | |
Myeloma bone disease: from biology findings to treatment approaches | |
Neutrophil Gelatinase--Associated Lipocalin and Cystatin C Are Sensitive Markers of Renal Injury in Patients With Multiple Myeloma. | |
Next generation flow cytometry for MRD detection in patients with AL amyloidosis | |
No significant improvement in the outcome of patients with Waldenström's macroglobulinemia treated over the last 25 years | |
Patient-centered practice in elderly myeloma patients: an overview and consensus from the European Myeloma Network (EMN) | |
Peripheral Blood Immune Profiling of Convalescent Plasma Donors Reveals Alterations in Specific Immune Subpopulations Even at 2 Months Post SARS-CoV-2 Infection | |
Phase 2 study of ofatumumab, fludarabine and cyclophosphamide in relapsed/refractory Waldenström’s macroglobulinemia | |
Prevention of bone disease and early detection of impending fractures in multiple myeloma patients can reduce morbidity and mortality: the necessity of interdisciplinary state-of-the-art treatment | |
Primary failure of bortezomib in newly diagnosed multiple myeloma--understanding the magnitude, predictors, and significance | |
Primary plasma cell leukemia presenting as secondary pulmonary alveolar proteinosis | |
Prognostication of the High-Risk WM Patient | |
Prophylactic antibiotics for the prevention of neutropenic fever in patients undergoing autologous stem-cell transplantation: results of a single institution, randomized phase 2 trial | |
Quantitative Diffusion-weighted Imaging of the Bone Marrow: An Adjunct Tool for the Diagnosis of a Diffuse MR Imaging Pattern in Patients with Multiple Myeloma | |
Real-world data on incidence, clinical characteristics and outcome of patients with macrofocal multiple myeloma (MFMM) in the era of novel therapies: A study of the Greco-Israeli collaborative myeloma working group | |
Real-world effectiveness and safety of ixazomib-lenalidomide-dexamethasone in relapsed/refractory multiple myeloma | |
Real-world outcomes and factors impacting treatment choice in relapsed and/or refractory multiple myeloma (RRMM): a comparison of VRd, KRd, and IRd | |
Recent insights into th pathophysiology of paroxysmal nocturnal hemoglobinuria | |
Recommendations for vaccination in multiple myeloma: a consensus of the European Myeloma Network | |
Renal pathology in patients with monoclonal gammopathy or multiple myeloma: monoclonal immunoglobulins are not always the cause | |
Response to bortezomib of a patient with scleromyxedema refractory to other therapies | |
Response to Comment-Osteonecrosis of the Jaw in Myeloma Patients Receiving Denosumab or Zoledronic Acid. Comment on Pivotal Trial by Raje et al. Published in Lancet Oncology | |
The Role of Low Dose Whole Body CT in the Detection of Progression of Patients with Smoldering Multiple Myeloma | |
Role of magnetic resonance imaging in the management of patients with multiple myeloma: a consensus statement | |
Sclerostin: a possible target for the management of cancer-induced bone disease | |
Screening for Gaucher disease among patients with plasma cell dyscrasias | |
Semaphorin 4D correlates with increased bone resorption, hypercalcemia, and disease stage in newly diagnosed patients with multiple myeloma. | |
Seroprevalence of Antibodies against SARS-CoV-2 among the Personnel and Students of the National and Kapodistrian University of Athens, Greece: A Preliminary Report | |
Serum concentrations of angiogenic cytokines in Waldenstrom macroglobulinaemia: the ratio of angiopoietin-1 to angiopoietin-2 and angiogenin correlate with disease severity | |
Serum free immunoglobulin light chain fingerprint identifies a subset of newly diagnosed multiple myeloma patients with worse outcome. | |
Short progression-free survival predicts for poor overall survival in older patients with multiple myeloma treated upfront with novel agent-based therapy | |
Significant reduction in the visits to the emergency room department during the COVID-19 pandemic in a tertiary hospital in Greece: Indirect victims of the pandemic? | |
Therapy-related myelodysplastic syndrome/acute leukemia after multiple myeloma in the era of novel agents | |
Timing and impact of a deep response in the outcome of patients with systemic light chain (AL) amyloidosis | |
TLR4/TIRAP polymorphisms are associated with progression and survival of patients with symptomatic myeloma. | |
Tobacco smoking and risk of multiple myeloma: A meta-analysis of 40 observational studies | |
Toll-Like Receptor 4 Activation Promotes Multiple Myeloma Cell Growth and Survival Via Suppression of The Endoplasmic Reticulum Stress Factor Chop | |
Treatment of light chain (AL) amyloidosis with the combination of bortezomib and dexamethasone | |
Treatment of patients with multiple myeloma complicated by renal failure with bortezomib-based regimens | |
Treatment recommendations for patients with Waldenström macroglobulinemia (WM) and related disorders: IWWM-7 consensus | |
Validation of the International Prognostic Scoring System (IPSS) for Waldenstrom's macroglobulinemia (WM) and the importance of serum lactate dehydrogenase (LDH) |